IGMS IGM Biosciences Inc

Price (delayed)

$9.42

Market cap

$553.77M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.71

Enterprise value

$481.16M

Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing ...

Highlights

IGM Biosciences's gross profit has surged by 99% YoY and by 15% QoQ

IGMS's revenue has surged by 99% year-on-year and by 15% since the previous quarter

IGM Biosciences's equity has decreased by 29% YoY and by 20% from the previous quarter

IGM Biosciences's quick ratio has decreased by 17% YoY and by 12% QoQ

Sector: Healthcare

Industry: Biotechnology

Website: http://igmbio.com

Peers: OMER OMGA

Key stats

What are the main financial stats of IGMS

Market

Shares outstanding

58.79M

Market cap

$553.77M

Enterprise value

$481.16M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

2.71

Price to sales (P/S)

231.35

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

225.9

Earnings

Revenue

$2.13M

EBIT

-$245.74M

EBITDA

-$232.05M

Free cash flow

-$204.61M

Per share

EPS

-$4.71

Free cash flow per share

-$3.91

Book value per share

$3.48

Revenue per share

$0.04

TBVPS

$8.09

Balance sheet

Total assets

$423.41M

Total liabilities

$220.18M

Debt

$40.51M

Equity

$203.23M

Working capital

$305.12M

Liquidity

Debt to equity

0.2

Current ratio

8.18

Quick ratio

7.96

Net debt/EBITDA

0.31

Margins

EBITDA margin

-10,894.2%

Gross margin

100%

Net margin

-11,568.8%

Operating margin

-12,369.1%

Efficiency

Return on assets

-53.5%

Return on equity

-103.2%

Return on invested capital

-78.5%

Return on capital employed

-64.5%

Return on sales

-11,537%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

IGMS stock price

How has the IGM Biosciences stock price performed over time

Intraday

23.14%

1 week

30.83%

1 month

8.53%

1 year

-13.42%

YTD

13.36%

QTD

-2.38%

Financial performance

How have IGM Biosciences's revenue and profit performed over time

Revenue

$2.13M

Gross profit

$2.13M

Operating income

-$263.46M

Net income

-$246.42M

Gross margin

100%

Net margin

-11,568.8%

IGM Biosciences's gross profit has surged by 99% YoY and by 15% QoQ

IGMS's revenue has surged by 99% year-on-year and by 15% since the previous quarter

IGM Biosciences's net margin has increased by 44% YoY and by 10% from the previous quarter

IGMS's operating margin is up by 42% year-on-year and by 10% since the previous quarter

Growth

What is IGM Biosciences's growth rate over time

Valuation

What is IGM Biosciences stock price valuation

P/E

N/A

P/B

2.71

P/S

231.35

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

225.9

The EPS is up by 11% year-on-year and by 5% since the previous quarter

The stock's P/B is 57% below its 5-year quarterly average of 5.1 but 4.8% above its last 4 quarters average of 2.1

IGM Biosciences's equity has decreased by 29% YoY and by 20% from the previous quarter

IGMS's revenue has surged by 99% year-on-year and by 15% since the previous quarter

IGMS's price to sales (P/S) is 32% less than its last 4 quarters average of 276.5

Efficiency

How efficient is IGM Biosciences business performance

The return on sales is up by 44% year-on-year and by 10% since the previous quarter

IGMS's return on equity is down by 39% year-on-year and by 13% since the previous quarter

The ROA has contracted by 15% YoY and by 8% from the previous quarter

The return on invested capital has declined by 13% year-on-year and by 10% since the previous quarter

Dividends

What is IGMS's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for IGMS.

Financial health

How did IGM Biosciences financials performed over time

The total assets is 92% greater than the total liabilities

The total assets has declined by 18% year-on-year and by 11% since the previous quarter

IGM Biosciences's quick ratio has decreased by 17% YoY and by 12% QoQ

IGM Biosciences's debt is 80% less than its equity

IGMS's debt to equity is up by 43% YoY and by 25% QoQ

IGM Biosciences's equity has decreased by 29% YoY and by 20% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.